Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.
Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.
Sells PCR test kits (reagents) plus the machines that run them; because reagents are generally tied to the instruments they run on, an installed instrument keeps pulling reagent orders. Sales jumped during the COVID-19 testing wave of 2020 to 2022 and then fell back as it turned to other disease areas and overseas markets.
In one line: A Chinese QIAGEN for molecular (PCR) diagnostics.
Moat: narrow (installed base, regulatory licence). Instrument-reagent lock-in and disease-testing registrations favor an incumbent supplier.
Headquarters: Changsha, Hunan, China · Employees: 2,128
Size Sansure Biotech (688289.SS) is a China Health Care company (Medical Specialties) with a market value of $1.24B, the 1795th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.53 on 18 Nov 2026.
Performance Over six months the shares fell 16.7%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 1.2% over the last twelve months (peer median +13.7%); the operating margin is 1.5% (peer median 11.6%).
Valuation It trades at 35.6× forward earnings against a peer median of 23.9× (5th most expensive of 16).
Capital Return on invested capital runs 2.5 points below its cost of capital (5.7% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.65B | CN¥1.64B | CN¥1.45B | CN¥1.00B | CN¥6.42B |
| Revenue growth | — | +13% | +45% | -84% | — |
| Gross profit | CN¥1.24B | CN¥1.08B | CN¥999M | CN¥621M | CN¥3.69B |
| EBITDA | n/a | CN¥364M | CN¥296M | CN¥119M | CN¥2.28B |
| Net income | CN¥112M | CN¥199M | CN¥276M | CN¥364M | CN¥1.94B |
| Free cash flow | -CN¥109M | -CN¥179M | -CN¥132M | -CN¥279M | CN¥2.09B |
| Capital expenditure | CN¥351M | CN¥370M | CN¥421M | CN¥391M | CN¥559M |
| Total debt | CN¥1.54B | CN¥1.16B | CN¥444M | CN¥95.4M | CN¥27.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sansure Biotech 688289.SS | $1.24B | -17% | -1% | 1% | 35.6× | n/a |
| Qiagen QGEN | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% |
| BGI Genomics 300676.SZ | $2.13B | -15% | 0% | -14% | 126.7× | n/a |
| Beijing Hotgen Biotech 688068.SS | $815M | -37% | +8% | -94% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688289.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -1.7% | 9th lowest of 21 |
| 6-month return | -16.7% | -10.4% | 8th lowest of 20 |
| Distance from 52-week high | -36.3% | -38.5% | 10th highest of 21 |
| Revenue growth (TTM) | -1.2% | +13.7% | 3rd lowest of 19 |
| Operating margin | 1.5% | 11.6% | 5th lowest of 20 |
| Forward P/E | 35.6× | 23.9× | 5th most expensive of 16 |
| ROIC minus cost of capital | -2.5 pp | +0.2 pp | 7th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |